A comprehensive hepatitis c viral kinetic model explaining cure

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 706-713

  Snoeck, E ^a   Chanu, P ^b   Lavielle, M ^c   Jacqmin, P ^a   Jonsson, E N ^a   Jorga, K ^b   Goggin, T ^b   Grippo, J ^b   Jumbe, N L ^b   Frey, N ^b  

^a Exprimo NV   (Belgium)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c INRIA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG INHIBITION; ERADICATION THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRION; VIROTHERAPY; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; KINETICS; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77952581566     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.35     Document Type: Article

References (40)

1. World Health Organization. Hepatitis C http://www.who.int/mediacentre/ factsheets/fs164/en. Accessed 15 September 2008.
2. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002\June 10-12, 2002. Hepatology 36, S3-S20 (2002).
3. Strader, D.B., Wright, T., Thomas, D.L. & Seef, L.B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 39, 1147-1171 (2004).
4. Fried, M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
5. Hadziyannis, S.J. et al.; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
6. Zein, N.N., Rakela, J., Krawitt, E.L., Reddy, K.R., Tominaga, T. & Persing, D.H. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann. Intern. Med. 125, 634-639 (1996).
7. Dixit, N.M., Layden-Almer, J.E., Layden, T.J. & Perelson, A.S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432, 922-924 (2004).
8. Perelson, A.S., Herrmann, E., Micol, F. & Zeuzem, S. New kinetic models for the hepatitis C virus. Hepatology 42, 749-754 (2005).
9. Neumann, A.U. et al. Hepatitis C viral dynamics in vivo and the antiviral efcacy of interferon-alpha therapy. Science 282, 103-107 (1998).
10. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586 (1996).
11. Wei, X. et al. Viral dynamics in human immunodefciency virus type 1 infection. Nature 373, 117-122 (1995).
12. Colombatto, P. et al. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir. Ther. (Lond.) 8, 519-530 (2003).
13. Zeuzem, S. The kinetics of hepatitis C virus infection. Clin. Liver Dis. 5, 917-930 (2001).
14. Layden, J.E. & Layden, T.J. Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology 35, 967-970 (2002).
15. Layden-Almer, J.E., Cotler, S.J. & Layden, T.J. Viral kinetics in the treatment of chronic hepatitis C. J. Viral Hepat. 13, 499-504 (2006).
16. Dahari, H., Lo, A., Ribeiro, R.M. & Perelson, A.S. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efcacy. J. Theor. Biol. 247, 371-381 (2007).
17. Callaway, D.S. & Perelson, A.S. HIV-1 infection and low steady state viral loads. Bull. Math. Biol. 64, 29-64 (2002).
18. Pomfret, E.A. et al. Liver regeneration and surgical outcome in donors of right-lobe liver grafts. Transplantation 76, 5-10 (2003).
19. Neumann, A.U. et al. Diferences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182, 28-35 (2000).
20. US Food and Drug Administration. Label information for Pegasys http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf.
21. US Food and Drug Administration. Label information for Copegus http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088576.pdf.
22. Samson, A., Lavielle, M. & Mentré, F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-efects model: Application to HIV dynamics model. Comput. Statist. Data Anal. 51, 1562-1574 (2006).
23. Karlsson, M.O. & Savic, R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82, 17-20 (2007).
24. Bernardin, F., Tobler, L., Walsh, I., Williams, J.D., Busch, M. & Delwart, E. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 47, 1446-1452 (2008).
25. Wodarz, D. Mathematical models of immune efector responses to viral infections: virus control versus the development of pathology. J. Comp. Appl. Math. 184, 301-319 (2005).
26. Dienstag, J.L. & McHutchison, J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130, 231-64; quiz 214 (2006).
27. Samson, A., Lavielle, M. & Mentré, F. The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-efects model. Stat. Med. 26, 4860-4875 (2007).
28. Heathcote, E.J. et al. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673-1680 (2000).
29. Zeuzem, S. et al. Peginterferon α-2a in patients with chronic hepatitis C. N. Engl. J. Med. 357, 124-134 (2007).
30. Reddy, K.R. et al. Efcacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33, 433-438 (2001).
31. Pockros, P.J. et al.; PEGASYS International Study Group. Efcacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am. J. Gastroenterol. 99, 1298-1305 (2004).
32. Lee, S.C. et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J. Clin. Microbiol. 38, 4171-4179 (2000).
33. Snoeck, E., Wade, J.R., Duf, F., Lamb, M. & Jorga, K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon α-2a (40KD) plus ribavirin. Br. J. Clin. Pharmacol. 62, 699-709 (2006).
34. Sherlock, S. & Dooley, J. Diseases of the Liver and Biliary System 10th edn. (Blackwell Science, Oxford, UK, 1998) 8.
35. Liou, T.C., Chang, T.T., Young, K.C., Lin, X.Z., Lin, C.Y. & Wu, H.L. Detection of HCV RNA in saliva, urine, seminal fuid, and ascites. J. Med. Virol. 37, 197-202 (1992).
36. Mc Sween, R.N.M., Anthony, P. P. & Scheuer, P.J. Pathology of the Liver 2nd edn. (Churchill-Livingstone, New York, 1987).
37. Delyon, B., Lavielle, M. & Moulines, E. Covergence of a stochastic approximation version of the EM algorithm. Ann. Statist. 27, 94-128 (1999).
38. Kuhn, E. & Laveille, M. Maximum likelihood estimation in nonlinear mixed efects models. Comput. Statist. Data Anal. 1020-1038 (2005).
39. Altman, D.G. & Bland, J.M. Diagnostic tests. 1: Sensitivity and specifcity. BMJ 308, 1552 (1994).
40. Bishop, Y.M., Fienberg, S.E. & Holland, P.W. Discrete Multivariate Analysis: Theory and Practice (MIT Press, Cambridge, MA, 1977).